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Testing the Accuracy of Total Cholesterol Assays in an External Quality-Control 
Program. Effect of Adding Sucrose to Lyophilized Control Sera Compared with Use 
of Fresh or Frozen Sera
Henk Baadenhugsen,1’5 Pierre N.M. Demacker,2 Marja Hessels,1 Geert J.M. Boerma,3 Theo J. Penders,4 
Cas Weykamp,4 and Hans L. Willems1
We studied the suitability of various types of human serum dependent differences in accuracy of various choles-
preparations to test the accuracy of total cholesterol mea- amply demonstrated (2-6), and
surements in the External Quality Assessment scheme in part of this variance has been attributed to the lack of
The Netherlands, in which ~180 laboratories participate. 
Checked against the certified Abell/Kendall Reference 
Method, large reagent-dependent negative biases were 
observed with lyophilized serum that was insufficiently 
cryoprotected. The biases for the reagents of Du Pont, 
Roche, and Beckman averaged -16.7%, -9.2% , and 
-7.6% respectively; the least bias, -0.4%, was obtained 
with reagent from Boehringer Mannheim. The beneficial 
effect of cryoprotection with sucrose was demonstrated by 
the decrease in interreagent variation from 5.4% to 1.9%, 
the latter value being comparable with the values for fresh 
and once-frozen pooled serum (1.3% and 1.7%, respec­
tively). We conclude that the detrimental effect of lyophili- 
zation on serum matrix can be minimized by suitable 
cryoprotection with 200 g/L sucrose.
Indexing Terms: sample handling/cryopreservation/ external qual­
ity assessment
With the advent of national cholesterol consensus 
agreements, as now have been reached in many coun­
tries, it is no longer acceptable for individual laborato­
ries to use their own lipid reference intervals with 
inherent, local method-induced biases. Instead, diag-
commutability —1 1  ) .
With few exceptions, most EQA schemes
material for logistical
concerning
performance 
ratories, on( must use control material all
resembles the 
human serum
commutability indicates that one potential source of 
error may be the use of animal sera; another may be 
the preparation procedure used for long-jterm storage. 
Both can result in lipoproteins that subsequently are 
suboptimally processed by reagents designed for anal­
ysis of fresh human sera. This is especially true after 
inadequate cryopreservation, which can denature apo­
protein B-containing lipoproteins.
Recently (12-15), sucrose was successfully used in 
the cryoprotection of lipoprotein(a), a lipoprotein that 
is even more rapidly denatured than the other apopro­
tein B-containing lipoproteins in serum. These results 
prompted us to evaluate the use of sucrose as a cryo- 
protectant in sera used in our EQA surveys. We de­
cided therefore to study the effects of sucrose addition
nostic strategy requires the application of fixed risk- to lyophilized serum preparations with respect to the 
evaluation cut points. Thus, laboratories must be able interlaboratory accuracy—comparing not only the ly- 
to deliver cholesterol results that are standardized to a ophilized preparation with and without added sucrose
central accuracy base.
To comply with the US guidelines, issued by the 
National Cholesterol Education Program, laboratories 
must have a method bias <3% from the Abell-Kendall 
(A/K) Reference Method and a between-run method 
precision better than 3% (1 ).6 Evaluating inaccuracy in 
the individual laboratory frequently involves External 
Quality Assessment (EQA). The existence of method-
1 Departments of Clinical Chemistry and 2 General Internal 
Medicine, University Hospital Nymegen;3 Department of Clini­
cal Chemistry, Sophia Children’s Hospital, Rotterdam; and 4 De­
but also untreated serum, and once-frozen serum prep­
arations.
Materials and Methods
Preparation of Pooled Human Serum
Patients’ serum samples that were stored at 4°C for 
<3 days, residuals of the clinical laboratory, were 
pooled in 200-mL portions. This was done according to 
the hospital policy of generally asking patients for 
consent to so proceed. Each pool consisted of material 
originating from at least 150 different patients. The
partment of Clinical Chemistry, Queen Beatrix Hospital, Winters- resulting nominal cholesterol concentration was very
constant between pools, being 5.3-5.6 mmol/L. Sera 
with apparent turbidity, excessive bilirubin, or hemo­
lysis were excluded from pooling. After pooling, the 
sera were centrifuged in 50-mL volumes at 3000g for 30 
min, after which the chylomicrons at the meniscus 
were removed by manual aspiration. Before distribu-
wyk, The Netherlands.
6 Address for correspondence: University Hospital Nymegen St. 
Radboud, Central Clinical Chemistry Laboratory, P.O. Box 9101, 
NL-6500 HB Nymegen, The Netherlands. Fax 4- 31 80 541743.
6 Nonstandard abbreviations: EQA, External Quality Assess­
ment; A/K, Abell-Kendall; and LDL, HDL, and VLDL, low-, high, 
and very-low-density lipoprotein.
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tion, the subpools were verified to be free of HIV and 
hepatitis A, B, and C antigens.
Sample preparation and subsequent lyophilization 
were based on procedures described by Wieland and 
Seidel (16) and Terlingen et al. (17). In brief, 200-mL 
portions were combined and processed in four different 
ways: (a) 5-mL aliquots (n = number of surveys = 1) 
were dispensed into brown neutral-glass vials and 
mailed by overnight post (ambient temperature at 
night, <15°C) to be analyzed within 24 h; (6) 5-mL 
aliquots (n = 4) were dispensed into the glass vials, 
frozen at —25°C, and mailed by overnight post in solid 
C 02, to be kept frozen until analysis; (c) 5-mL aliquots 
(n = 27) were dispensed into the glass vials, frozen at 
-25°C, and lyophilized; (d ) sucrose (200 g/L, final 
concentration) was added and 7-mL aliquots (n = 23) 
were dispensed into the glass vials, frozen at -25°C, 
and lyophilized. All aliquots were dispensed with an 
imprecision of <0.2% as determined by weighing at 
random 1 of each 50 vials before and after filling. The 
aliquots dispensed from the sucrose-containing pools 
were 7 mL to correct for volume changes. We fine-tuned 
the dispensing by calculating a factor based on the 
measured sodium concentration. None of the samples 
was supplemented with external cholesterol.
For lyophilization we used a Virtis Consol 12 
(Gardiner, NY). The samples were placed into the 
freeze-dryer with a shelf temperature of —20°C. During 
the next 50 h, the temperature was increased to -  14°C 
and the pressure was reduced to 1.3 Pa. The tempera­
ture was increased to 0°C during 40 h, then to 20°C 
during 7 h, and held there for 10 h. The samples were 
capped while still under reduced pressure. The mois­
ture content was checked by a Karl Fisher procedure 
with Metrohm analytical equipment (Metrohm, Heri- 
sau, Switzerland); it was always <0.5%.
Commercially Available Sera
To evaluate the suitability (or lack thereof) of commer­
cially available control sera to serve as control for accu­
racy, we selected 10 different serum preparations for 
forwarding to the participants in 2 to 13 surveys (see 
Table 1). All were delivered in the knowledge that they 
would be used in the Netherlands EQA Scheme (18 ).
Characterization of Serum Preparations
Lipoprotein integrity was studied by means of den- 
sity-gradient ultracentrifugation; the serum sample 
was stained with Coomassie Brilliant Blue before ul­
tracentrifugation, which resulted in blue-colored li­
poprotein bands within the density gradient after ul­
tracentrifugation (19). We also characterized serum 
preparations by lipoprotein electrophoresis with the 
Paragon system (Beckman Instruments Diagnostics, 
Brea, CA); staining was performed with Sudan Black. 
Turbidity of the reconstituted lyophilized serum prep­
arations was measured by absorbance at 620 nm. All 
serum specimens under study were also analyzed with 
the Centers for Disease Control and Prevention (Atlan­
ta, GA) standardized A/K Reference Method (20 ) in the
Lipid Reference Laboratory of one of the authors
(G.J.M.B.).
Interlaboratory Comparison Surveys
The data presented for the prepared sera stem from 
the observations of one survey in which untreated 
serum was analyzed, four surveys in which once-frozen 
serum was used, and 23 and 27 surveys with lyophi­
lized serum respectively with or without sucrose at 200 
g/L. For logistical reasons, the study of the four most 
important serum preparations (untreated liquid, fro­
zen liquid, lyophilized without, or lyophilized with 
sucrose) could not be performed with one combined 
source pool in the same survey. We therefore consid­
ered the following two combinations of serum prepara­
tions from the same source pool in the same survey: (a) 
comparing untreated serum with the lyophilized serum 
without sucrose, evaluated once; or (b) comparing the 
frozen serum with both lyophilized serum prepara­
tions, i.e., without and with sucrose.
The standard procedure allowed for each participant 
to specify the analytical method used in terms of type of 
instrumentation and the source of reagents. We ana­
lyzed the returned results with respect to the source of 
the reagents, finding this to be more decisive than 
differentiation according to the type of instrument 
because some of the “open analyzer” systems allow 
users to choose various specific reagents. The users of 
Boehringer Mannheim (Mannheim, Germany) re­
agents represented the largest reagent group (80 labo­
ratories, 43%). The next largest group consisted of 
Kodak Ektachem (Eastman Kodak, Rochester, NY) 
users (26 laboratories, 14%), followed by Beckman with 
15 laboratories (8%), Bayer Diagnostics (Leverkusen, 
Germany) with 14 laboratories (7%), E. Merck Diag­
nostics (Darmstadt, Germany) with 9 laboratories 
(5%), Hoffmann-La Roche (Basel, Switzerland) with 8 
laboratories (4%), Du Pont (Wilmington, DE) with 6 
laboratories (3%), and Baxter (Dudingen, Switzerland) 
with 6 laboratories (3%).
The data for commercial control sera reflect serum 
preparations from Randox Labs, Crumlin, UK (13 
surveys with Randox™, lot nos. SE1099, SN 1098, 
067SE, 038SN, 002UE, 002UN, 032SN, 078SE, 
UE1559, SL1097, 064SN); Nycomed A/S, Oslo, Norway 
(6 surveys with Autonorm™, lot nos. 4003, 11014, 
11015, 212043); Bio-Rad Labs., Anaheim, CA (7 sur­
veys with Lyphochek™ bovine, lot nos. 37102, 40301, 
40302; 6 surveys with Lyphochek™ human, lot nos. 
44101, 44102, 48802, 54801, 54802, 60802; 5 surveys 
with liquid Liquichek™, lot nos. 74031, 74032, 59401, 
59402); Baxter Healthcare, Dade Division, Miami, FL 
(2 surveys with Moni-Trol™, lot nos. 615002, 616002); 
Human GmbH, Taunusstein, Germany (4 surveys with 
Serodos™, lot nos. 6863, 6865, 6790); Boehringer 
Mannheim (4 surveys with Precinorm™/Precipath™, 
lot nos. 187470, 229415); Merck (5 surveys with Quali- 
trol™, lot nos. 326, 390, 3410, 10937, 11307); and 
Laboratoires BioMerieux, Marcy l’Etoile, France (4
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surveys with Lyotrol™, lot nos. 634361A, 634371A, 
64473OA, 735530A).
Calculations and Statistical Tests
For each survey, the reagent-group-specific mean 
values were calculated after elimination of statistical 
outliers. Identification of outliers was carried out at the 
1% uncertainty level as described earlier (18). These 
reagent-specific mean values were thereafter compared 
with the known A/K Reference Method value to estab­
lish the percentage bias with the A/K value. To test 
whether these percentage biases obtained for the var­
ious serum preparations (frozen, or lyophilized without 
or with 200 g/L sucrose) differed from one another, we 
used the nonparametric two-tailed Wilcoxon test. For 
each survey, we also calculated the variation in the 
reagent-specific mean values and expressed this as the 
interreagent CV. This is a very sensitive measure for 
representing the magnitude of a possible matrix-in­
duced intermethod variation. Where appropriate, these 
CV values were also averaged over the number of 
surveys.
in the fraction <1.006 kg/L. The experimental sera we 
developed displayed sharp and well-separated HDL2 
and HDL3 bands, independent of the use of sucrose. 
However, these materials also contained flaky VLDL.7
Reconstituted control sera cryoprotected with su­
crose at 0, 70, 140, and 200 g/L showed a gradual
nm
of 1.5, 0.8, 0.4, and 0.3, respectively.
Interlaboratory Comparison Surveys
Averaged over the number of surveys, the percent­
ages of bias from the certified A/K Reference Method 
values found for the various reagent group mean val­
ues are shown in Table 1. For comparison, the results 
for one single survey with material derived from the 
same pool are also included. The results of these
singular surveys did not differ significantly (P 0 .01)
Results
Serum Characterization
from the aggregated data from all surveys for the 
materials in question. Because the aggregated data 
consist of results obtained over 2 years, we also looked 
for possible shifts or trends that might confound con­
clusions to be drawn from the total data. We specifi­
cally looked for any drift or trend in the two reagents 
giving the most different effects, i.e., the Du Pont and 
the Boehringer Mannheim results for (the in-house- 
prepared lyophilized sera without sucrose. The per-
Agarose gel electrophoresis examples of three typical centage difference from the A/K values found in four
commercial “animal” control sera and a typical com-•/ X
mercial “human” control serum are shown in Fig. 1.
surveys for the late 1992, mid-1993, and late 1993 
surveys was respectively -16.9% (SD 3.2%), —17.7%
Also shown are the lipoprotein patterns of both kinds of (SD 1.8%), and —17.9% (SD 2.7%) for the Du Pont 
prepared lyophilized sera: one without and the other reagent, and -0.2% (SD 2.2%), —1.4% (SD 0.9%), and
with the added 200 g/L sucrose as cryoprotectant. For 0.8% (SD 0.6%) for the Boehringer Mannheim re-
comparison the pattern for three once-frozen human agent. No significant drift or trend was detected.
serum pools are also shown. The most obvious finding was the large dispersion of
some of them
For the animal sera the most stain-positive sub- the differences of the reagent-specific mean values 
stance is encountered in the a region, with a smear of from the A/K Reference Method values for the commer- 
indiscriminate staining in the |3/pre-j3 region seen fre­
quently. All lipoprotein bands of the commercial sam­
ple of human origin are diffuse, indicating some loss of 
structure. The sera we prepared, both without and When the control sera with denatured material were analyzed by conventional sequential ultracentrifugation, a procedure in
1
with sucrose, exhibited well-defined a- and /3-lipopro- which no contact with the strongly ionic salts occurs, the d < 1.006 
tein bands, but the pre-/3 band is missing somewhat, kg/L material still contained white flakes.
presumably because of a degree of dénaturation during 
the lyophilization process, even in the presence of 
sucrose.
The same series of control sera were also analyzed by 
density-gradient ultracentrifugation (Fig. 2). The ani­
mal serum is strongly icteric, resulting in a greenish 
appearance upon ultracentrifugation (yellow bilirubin 
mixed with Coomassie Brilliant Blue stain). Animal 
lipoproteins can be frequently recognized from their 
hyper-a-lipoproteinemia. In these sera we also fre­
quently detected denatured low-density lipoprotein
(LDL), which could be recognized by flakes floating in Fig. 1. Agarose gel electrophoresis of control sera of different origins 
the LDL density range. The commercially available with a-, 0, and pre-0-lipoproteins at the migration distances 1, 2,
serum of human origin typically showed a diffuse 
high-density lipoprotein (HDL) region, in which HDL2 
and HDL3 could be barely distinguished. The very-low- 
density lipoprotein (VLDL) fraction also usually ap­
peared to be denaturated, with flaky material present
2
3
and 3, respectively.
(a) Experimental serum containing 200 g/L sucrose; (b) human serum from 
commercial source (BioMérieux Lyotrol 735530A); (c) experimental serum 
without sucrose; (d, e, f) once-frozen human serum pools; (g, h, I) animal sera 
from commercial source (Technicon Testpoint IV09316, Bio-Rad Lyphochek 
40302, and Randox 002UE, respectively). Except for d, e, and f, all sera were 
lyophilized specimens after reconstitution.
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four surveys involving once-frozen serum, the results 
for once-frozen serum also showed a positive mean 
difference from the A/K values: +2.7% (SD 0.7%). For 
the lyophilized specimens, the bias between the su­
crose-containing sera in relation to the A/K values 
resembled those for the fresh serum and the frozen 
sera; i.e., the mean difference was +3.8% (SD 1.1%). In 
contrast, the sera lyophilized without sucrose gave a 
mean difference of -5.8% (SD 1.6%)—the overall neg­
ative bias being highly influenced by the large negative 
differences found for the reagent groups of Du Pont 
(-16.7%), Roche (-9.2%), and Beckman (-7.6%).
The reagent-specific mean relative biases from the 
A/K values for fresh serum, frozen sera, and lyophilized 
sera with sucrose belonged to one homogeneous statis­
tical population; the results for the lyophilized sera 
without sucrose belonged to another. The comparabil­
ity among the first three sample types is also demon­
strable by the similarity of their interreagent CVs 
, and Lyotrol) resembled 1.3%, 1.7%, and 1.9%, respectively, for fresh serum,
prepared sera without sucrose; i.e., frozen sera, and lyophilized sera with sucrose: the
• /
nt-apecific group mean values were always interreagent CV for lyophilized sera without sucrose,
t
h
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d
f t
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1
ity-gradient ultracentrifugation of various control sera 
t the top of the tube (7), followed by LDL (2), HDL2 (3),
‘ serum proteins (5).
ft I are the same as In Fig. 1. Note the variable boundary of 
protein fraction, related to the presence of sucrose in the sample.
the A/K Reference Method values. This
for the reagent group mean differences
however, was 5.4%.
The data for the sera we prepared can be used to
reflected in the relatively high values differentiate between pure method-related effects,
mterreagent CVs, which were ~3-4%. which arise from the differences between the prepared
for the prepared sera are shown in Fig. samples and fresh serum, and effects that are induced
for the fresh serum, averaged over all re- by freezing and (or) lyophilization. The effect of lyoph-
showed a positive mean difference of ilization, differentiated for the presence or absence of
the A/K reference value. Averaged over the sucrose, can be interpreted as the combined effect of
1 bias from A/K values and mean 
serum preparations.
Mean (SD) % bias with reagent from Interreagent
% ^ f
Frozen
t
f t  £
Matrix
No. of 
surveys Baxter Beckman Boehr. M. Du Pont Kodak Merck Roche Bayer
CV, %
(range)
Animal® 6 2.2 (4.2) 1.2 (0.7) 4.0 (2.9) -4 .6  (1.2) 5.0 (3.4) 1.3 (2.7) 3.6 (5.1) 4.0 (2.4) 3.7 (2.6-4.5)
Bovine 13 2.4 (2.9) — 1.5 (1.4) 0.5 (1.8) -4 .9  (2.2) -3 .4  (3.2) -0 .6  (1.8) 0.9 (3.2) •-0 .3  (2.2) 2.7 (1.9-3.6)4
Bovine 7 - 3.6 (3.2) -5 .5  (6.1) — 1.7 (4.0) -9 .5  (7.7) -3 .9  (4.8) -4 .5  (6.3) -1.1 (6.9) ■-0 .7  (3.2) 4.3 (2.1-6.7)
Animal* 2 1.1 (0.1) -1 .7  (1.0) 2.2 (1.3) —8.4 (3.4) 7.1 (2.5) -1 .7  (1.6) 3.0 (2.7) 2.3 (0.1) 4.4 (4.2~4.6)
Human 6 6.8 (3.7) -6 .4  (4.7) ■"3.6 (3.4) -12.2  (4.9) -5 .5  (2.7) -8 .2  (4.7) -6 .5  (4.4) •-1 .8  (1.5) 4.8 (1.8-8.0)
Human 6 2.2 (2.9) ■ 1.0 (4.4) 0.6 (0.5) -4 .3  (4.9) -5 .6  (3.9) —2.2 (2.9) “ 1,4 (2.4) 0.5 (1.7) 2.9 (1.1-5.6)
Human 4 0.4 (1.2) 1.7 (3.3) 1.4 (1.6) -1 .6  (3.2) -0 .1  (4.5) —0.6 (1.8) 4.6 (5.5) 1.2 (2.8) 2.8 (2.1-3.7)
Human 4 7.2 (2.4) 7.0 (3.4) -5 .0  (2.2) “ 13.2 (2.9) —3.4 (2.2) — 6.6 (3.4) -8 .9  (2.6) -4 .3  (2.8) 3.4 (2.5-4.0)
Human 5 0.8 (4.0) 1.4 (2.7) 1.4 (1.6) ■-3.8 (2.0) 1.6 (5.1) 1.1 (1.8) 1.0 (4.7) 3.0 (2.9) 3.0 (2.6-3.4)
Human 4 0.7 (1.4) 5,8 (3.0) 0.7 (2.4) -12.1 (3.8) -1 .9  (2.4) -1 .0  (1.8) -5 .5  (4.2) -1 .9  (1.1) 4.3 (2.9-5.4)
Human 1 0.1 3.5 2.2 3.3 0.9 2.4 2.7 4.0 1.3
Human 4 3.6 (3.6) 3.5 (0.8) 2.2 (0.4) -0 .3  (1.0) 4.8 (1.0) 3.4 (1.4) 2.2 (0.6) 2.2 (0.6) 1.7 (1.4-2.7)
Human 27 * -3.8 (2.2) -™ 7.6 (1.8) -0 .4  (1.5) -16.7(2.3)
>
-4 .6  (4.7) -3 .4  (2.5) -9 .2  (2.9) -3 .1  (1.6) 5.4 (2.4-7.3)
Human 23 4.4 (2.3) 3.5 (1.8) 4.1 (1.5) 2.1 (2.4) 5.4 (2.3) 2.9 (1.5) 5.1 (3.4) 3.1 (1.7) 1.9 (0.8-2.7)
Human 1 —4.7 — 5.8 —0.6 -18.3 -4 .9 —3.4 -12.1 -1 .0 6.0
Human 1 0.9 3.4 2.0 —0.2 5.0 1.5 2.4 2.4 1.4
Human 1 3.5 -9.1 0.6 14.0 -1 .7 -2 .9 -5 .3 -2 .8
4.6
A
Human 1 3.6 4.3 3.0 1.7 7.5 2.1 2.8
1.9 2.0
m £ i  *  k ' iiinimr characterized.
• J t '
M a id  and cryoprotectad with 200 g/L sucrose.
from the sama respective pool and combined into one survey.
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Baxter
□  Beckman
Boehringer M.
Du Pont
Kodak
Merck
□ Roche
Bayer
Native Frozen Lyoph. 
0% sucrose
Lyoph.
20%  sucrose.
Fig. 3. Reagent-mean characteristics of four different types of control serum—fresh (native), once-frozen, and lyophilized without and with 
sucrose (200 g/L)—with respect to the mean percentage difference from the A/K Reference Method values observed in EQA surveys for the 
material in question.
Error bars represent 1 SD.
the freezing, freeze-drying, and reconstitution pro- centrations with most reagents, the reagents of Du 
cesses. Fig. 4 illustrates the effect of these processes on Pont, Beckman, and Roche being affected most. The
the assayed results. The inherent method-related dif- data for lyophilization with sucrose show that the
■
presence of sucrose results in only minor deviationsferences with the A/K value are shown as “Method 
effect.” The freezing effect, obtained by subtracting the (<3%) for all reagents studied, 
values for “fresh” from those for frozen sera (Table 1), 
shows that the reagents of Baxter (+3.7%), Kodak 
(+3.7%), and Du Pont (-3.6%) are most affected by the 
freeze-thaw cycle. Lyophilization without sucrose 
(data after subtraction from the “Frozen” data in Table
Discussion
To assess the quality of the determination of total 
serum cholesterol, one must consider two factors: in- 
1) results in greatly underestimated cholesterol con- tralaboratory imprecision, which has to be low, and
JC
$œoc0)Û)
it:
¡5
10
5
0 ■ V
-5
-10
-15
-20 -I
1 » I »lí» A-"Lh.-» U . J Í .  H.— —  *- « ' > , r  » - , ^ » - , - ^ 1»-^ .......y,—  ... .-r u ■ *nnH-i-pi i M-s •■•i ii*. r , , , -»n -i k .1 -.írnj i t J I . ; K i M < | | < i i M u  iav4 i í M « < . k « i  i f *  « “i • - ¡ • J  •u h » ^ . . \ i a ^ í  », ■»*'*<-« l“i> « ,
« > ^ » * « « «  ‘1» — . iri.'i*..«« »■ I f ....... ~ - n  A L  . > > í.» V. - .-.».ï-,n.|r*Vr-i'-‘''‘'i .. ■•►«•r •>i*.iii< ..-.‘V p  fi.i-i ’m -  H i * * '- P  i ►»■■*<** V t  it' r > + r v w , J  » e r  A - ' f  ~  + *  '“i  •
4 H l M i i y i w i  \ •> » - 1  A
1 1- s -r '** i .i— --' * - . h o t  V f # * ' i i * r r « V  ■“ - t c - . . «*. . . J*- ' ' . J.. 4 IUl>
4«. PJJ ,
■ ^ 1  >■ t  ■— * . i > -  — . . a - . . . . » -  .  w  I  > «  ^  M  r  '  *  > •  - 1 . ^ .  ^ ^  . 1*
Method
effect
Freezing
effect
Lyoph. effect 
0%  sucrose
— c-l
■ ( M & A }
•  i » . »  -  •
“t L *k w  -—
Lyoph. effect 
20%  sucrose
. . . 1 1  .> t  K ■. »<-• ,t í ' - -j.....il^ji*.■.— •/ »».s /■ ■» i— i-¿>i-t a j í  f  i « i í » »Ai**.*<• v t n i *
■ •  • - i • i .  .* “ • .  *. 1  • « - i —  -  . .  i  .  r  .  i  • *  - ,  -  t -  - *  i - '  • “  - h a i .
. 1 ^ - ,  » -----.---------- >A«->-1.i
Baxter
□ Beckman 
Boehringer M. 
m Du Pont
0  Kodak
Merck
Roche
Bayer
Fig. 4. Differentiation of the effects of differences in methods, frozen vs fresh, frozen vs lyophilized without sucrose, and frozen vs lyophilized 
with 200 g/L sucrose (20% sucrose) on the different reagent-specific relative biases with the A/K Reference Method values.
Method effect bars represent the percentages difference for the native fresh serum (same as in Fig. 3). Values for the freezing effect are obtained by subtracting 
the values for the fresh specimen from the mean values obtained for the frozen samples. “Lyoph. Effect 0% sucrose” and “Lyoph. Effect 20% sucrose" values 
are likewise obtained by subtracting the values for the frozen specimens from the corresponding 0%  and 20% sucrose values (Table 1 and Fig. 3).
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accuracy. The US guidelines recommend a maximum 
intralaboratory CV of 3%—a value we believe can be 
reached by the majority of laboratories, as judged from 
own experience (21) and the literature (22). As for
(this publication; corrected data of Fig. 4)], followed by 
Beckman/Synchron [-3.6% (6), -5.5% (10), and 
-11.1% (this publication)]. The negative matrix bias 
we saw for Roche reagents, -11.4%, can be compared
accuracy, reliable performance evaluation of both par- with the finding of Ross et al. (6) of -4.4%. 
ticipants and methods, as classically carried out by Crucial in these observations is the conclusion that 
EQA surveys, is frequently hampered by the fact that lyophilization as such induces matrix biases having
the control sera used in such evaluations are not 
comparable with the fresh human serum matrix and
different consequences for the various (enzymatic) re­
agents used in the total cholesterol assay. Demacker et
thereby induce serious method/reagent/analyzer-de- al. (2), for example, already indicated that the activity
pendent differences that obscure assessment of the real and specificity of the cholesterol esterase used can be
laboratory performance with patients’ specimens. This critical. Moreover, the cholesteryl esters in the lipopro- 
drawback is especially true in analyses for total serum tein core can be hydrolyzed only after disruption of the
cholesterol. We therefore have studied some of the lipoproteins by a suitable detergent (23 ). The effect of
above-mentioned variables in a special survey with the detergent may be sufficient when pancreatic cho-
unadultered human serum. lesterol esterase is used but insufficient for complete
In our approach, control sera were evaluated by hydrolysis by the bacterial esterase. Comparable infor­
m ing variations in the species from which the serum mation on the importance of the kind of cholesterol 
originated, either commercially available or prepared esterase is given in the studies of Noel et al. (24) and 
by us and either cryoprotected with 200 g/L sucrose or Tel and Berends (25).
not. By dens ity-gradient ultracentrifugation, agarose The lyophilization of serum pools may affect some or
gel electrophoresis, and turbidity measurements, we all classes of lipoproteins. In the process of lyophiliza-
could show that the physical aspects of the various tion, the freezing step is the most crucial one. As ice
control sera were sometimes strikingly different from crystals are formed, the remaining interstitial fluid
those obtained for the fresh controls: Lipoprotein bands becomes overconcentrated; thus, the freezing cycle
of pooled serum lyophilized in the absence of sucrose means a dehydrating process with its accompanying
were less sharp and contained more denatured lipopro- denaturing effect. After reconstitution, therefore, the
teins than when lyophilized in the presence of sucrose. lyophilized pools are more turbid than untreated or
For the commercially available sera, the method used frozen serum. The change in turbidity thus reflects the
for cryoprotection is unknown, but some sera clearly change in the size and shape of the lipoproteins. This
contained large flakes, indicating LDL dénaturation. dénaturation gives rise to a decreased solubility,
The analytical methods used, density-gradient ultra- thereby hampering the availability of the lipoproteins
centrifugation and agarose electrophoresis, lack dis- for the enzymatic esterase and oxidase processes. Sev-
criminatory power to identify slight differences in de- eral studies with commercially available sera have
naturation. However, by comparing the relative shown that these kinds of phenomena play an impor-
performance of the various control sera, preparations tant role. Kroll and Chesler (9) reported prolonged
could be identified for which the interreagent variation enzymatic reaction times before lyophilized specimens
was comparable with that for fresh serum. In this way, reach absorbance equilibrium and noted differing sus-
we could show that, for short-term storage, once-frozen ceptibilities for the different enzymic formulations
serum, sucrose-preserved serum, and some commer- used in the Du Pont aca and Technicon RA-1000
eially available sera were more reliable than others. By systems to have suboptimal reaction rates. They also
appropriate rearrangement of the data we showed that commented on the optimal surfactant concentration in
some reagents or reagent/analyzer combinations were tests with lyophilized control material (26). The formu-
influenced by even the slightest denaturation of li- lation of the Boehringer Mannheim reagent kit con-
poproteins. For simple freezing and thawing, for in- tains additional lipolytic enzymes, which may help in
stance, the reagents from Baxter, Du Pont, and Kodak sufficiently disrupting also the denatured lipoproteins,
were influenced by >3%, albeit not always in the same thereby rendering this kit one of the most so-called
direction. matrix-robust methods. Finally, our present findings
The detrimental effect of lyophilization on the accu- support earlier reports of Wieland and Seidel (16),
racy of the determination of total cholesterol has also Sgoutas and Tuten (12, 13), and Borque et al. (14) on
been studied by the groups of Ross et al. (6 ), Kroll et al. the beneficial effect of sucrose as cryoprotectant during
9 )t and Naito et al. (ICO, whose studies revealed the freeze-drying process.
In conclusion, we have demonstrated the significant
comparable reagent-related differences. Whereas some 
reagents, including those from Boehringer Mannheim,
to have no or modest matrix-induced bias, improvement of the interreagent variation in the de-appear
others show considerable matrix error with lyophilized termination of total cholesterol and the overall much
control sera. The reported errors (6, 8,10),  to a large closer resemblance of sucrose-protected lyophilized
agree with our findings. The Du Pont/Dimen- control serum to fresh or once-frozen serum, appar-
aion method group showed the largest matrix-induced ently, therefore, ameliorating the detrimental lyophili-
! ”“11.6%(6'), -14.3% (8), ~8.9% (10), and -16.3% zation effects. Accordingly, lyophilized control sera
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with added sucrose may better serve the purpose of 
judging analytical accuracy in most routine cholesterol 
assay techniques than do unprotected control sera. In 
spite of having these tools for carrying out better 
intercomparability cholesterol studies, we still urge 
manufacturers to continue their search for developing 
and producing stabilized control material that will best 
mimic the characteristics of fresh human serum for use 
as calibrators. Only the fairly large-scale availability of 
such serum products can satisfy the need for choles­
terol assays to be traceable to the necessary accuracy 
level as provided by official and recognized reference 
laboratories.
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